GSK
Precision Cancer Consortium Launches With Bayer, GSK, Roche, Novartis as Founding Members
The organization of pharmaceutical and biotechnology firms aims to increase access to genomic testing for cancer patients.
FDA Approves GlaxoSmithKline's Jemperli, Roche’s Ventana CDx for dMMR Solid Cancers
The approval expands the label for GSK's anti-PD-1 agent dostarlimab, which the FDA initially approved in April for patients with dMMR endometrial cancers.
FDA Approves GSK's Jemperli With Ventana CDx for dMMR Endometrial Cancer
The FDA also approved the Ventana MMR RxDx panel as a companion diagnostic to select endometrial cancer patients for treatment with dostarlimab.
COVID-19 Pandemic Accelerated Development of CRISPR as a Diagnostic Platform in 2020
The pace of development for CRISPR-based infectious disease assays increased as the pandemic progress
Adaptive Biotechnologies, GlaxoSmithKline Collaborate on MRD Testing
In a non-exclusive deal, GlaxoSmithKline will use Adaptive Biotechnology's NGS-based ClonoSeq test to assess MRD across its hematology portfolio.